Human pharmacokinetics of an analogue of atrial natriuretic factor.
The pharmacokinetics of ANP-270, a 26 amino acid analogue of alpha human natriuretic factor (alpha-hANF) with a prolonged effect on isolated arterial preparations, has been studied in 40 healthy males, in a double-blind placebo controlled investigation. Placebo or ANP-270 0.3, 1.5 or 3.0 micrograms/kg were given by intravenous bolus injection, each to groups of 10 subjects. Blood samples were assayed for ANP-270 by a specific sandwich ELISA. The disappearance of ANP-270 from plasma followed a two-compartment decay, with mean distribution and elimination half-lives of 2.6 min (n = 30) and 10.6 min (n = 20), respectively. These estimates were similar to those obtained by other investigators for alpha-hANF. Their brevity explains the lack of a prolonged effect of ANP-270 in vivo compared to alpha-hANF.
Ingwersen
S H
SH
Pharmacokinetics Research, CNS Division, Novo Nordisk A/S, Maaloev, Denmark.
Eiskjaer
H
H
Schmiegelow
M
M
Pedersen
E B
EB
D000328:Adult; D009320:Atrial Natriuretic Factor / Q000097:blood / Q000493:pharmacokinetics*; D004311:Double-Blind Method; D004797:Enzyme-Linked Immunosorbent Assay; D006801:Humans; D008297:Male; D008875:Middle Aged; D010446:Peptide Fragments / Q000097:blood / Q000493:pharmacokinetics*; D012016:Reference Values; D012680:Sensitivity and Specificity
C472955:NPPA protein, human; D010446:Peptide Fragments; C074817:atrial natriuretic factor 270; D009320:Atrial Natriuretic Factor